Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8551 to 8565 of 8908 results

  1. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Discontinued Reference number: GID-TA11344

    Technology appraisal guidance
    Discontinued

  2. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Discontinued Reference number: GID-TA11467

    Technology appraisal guidance
    Discontinued

  3. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-TA11569

    Technology appraisal guidance
    Discontinued

  4. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-NG10404

    NICE guideline
    Discontinued

  5. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    Discontinued Reference number: GID-TA11401

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Discontinued Reference number: GID-TA11093

    Technology appraisal guidance
    Discontinued

  7. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    Discontinued Reference number: GID-TA11433

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  9. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    Discontinued Reference number: GID-TA10568

    Technology appraisal guidance
    Discontinued

  10. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    Discontinued Reference number: GID-TA10598

    Technology appraisal guidance
    Discontinued

  11. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  12. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  13. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    Discontinued Reference number: GID-TA10779

    Technology appraisal guidance
    Discontinued

  14. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued

  15. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Discontinued Reference number: GID-TA11018

    Technology appraisal guidance
    Discontinued